Literature DB >> 30784672

Cardiac Magnetic Resonance and Cardio-Oncology: Does T2 Signal the End of Anthracycline Cardiotoxicity?

Anthony F Yu1, Angel T Chan2, Richard M Steingart2.   

Abstract

Entities:  

Keywords:  CMR; anthracycline; cardio-oncology; cardiotoxicity; doxorubicin

Mesh：

Substances：

Year:  2019        PMID： 30784672      PMCID： PMC6544355          DOI： 10.1016/j.jacc.2018.11.045

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  16 in total

1.  Improved detection of myocardial involvement in acute inflammatory cardiomyopathies using T2 mapping.

Authors:  Paaladinesh Thavendiranathan; Michael Walls; Shivraman Giri; David Verhaert; Sanjay Rajagopalan; Sean Moore; Orlando P Simonetti; Subha V Raman
Journal:  Circ Cardiovasc Imaging       Date:  2011-10-28       Impact factor: 7.792

2.  Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Saro H Armenian; Christina Lacchetti; Ana Barac; Joseph Carver; Louis S Constine; Neelima Denduluri; Susan Dent; Pamela S Douglas; Jean-Bernard Durand; Michael Ewer; Carol Fabian; Melissa Hudson; Mariell Jessup; Lee W Jones; Bonnie Ky; Erica L Mayer; Javid Moslehi; Kevin Oeffinger; Katharine Ray; Kathryn Ruddy; Daniel Lenihan
Journal:  J Clin Oncol       Date:  2016-12-05       Impact factor: 44.544

3.  Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.

Authors:  Mônica Samuel Avila; Silvia Moreira Ayub-Ferreira; Mauro Rogerio de Barros Wanderley; Fatima das Dores Cruz; Sara Michelly Gonçalves Brandão; Vagner Oliveira Carvalho Rigaud; Marília Harumi Higuchi-Dos-Santos; Ludhmila Abrahão Hajjar; Roberto Kalil Filho; Paulo Marcelo Hoff; Marina Sahade; Marcela S M Ferrari; Romulo Leopoldo de Paula Costa; Max Senna Mano; Cecilia Beatriz Bittencourt Viana Cruz; Maria Cristina Abduch; Marco Stephan Lofrano Alves; Guilherme Veiga Guimaraes; Victor Sarli Issa; Marcio Sommer Bittencourt; Edimar Alcides Bocchi
Journal:  J Am Coll Cardiol       Date:  2018-03-11       Impact factor: 24.094

4.  Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).

Authors:  Xavier Bosch; Montserrat Rovira; Marta Sitges; Ariadna Domènech; José T Ortiz-Pérez; Teresa M de Caralt; Manuel Morales-Ruiz; Rosario J Perea; Mariano Monzó; Jordi Esteve
Journal:  J Am Coll Cardiol       Date:  2013-04-10       Impact factor: 24.094

5.  Risk factors for doxorubicin-induced congestive heart failure.

Authors:  D D Von Hoff; M W Layard; P Basa; H L Davis; A L Von Hoff; M Rozencweig; F M Muggia
Journal:  Ann Intern Med       Date:  1979-11       Impact factor: 25.391

6.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity.

Authors:  Sui Zhang; Xiaobing Liu; Tasneem Bawa-Khalfe; Long-Sheng Lu; Yi Lisa Lyu; Leroy F Liu; Edward T H Yeh
Journal:  Nat Med       Date:  2012-10-28       Impact factor: 53.440

Review 7.  Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review.

Authors:  Paaladinesh Thavendiranathan; Frédéric Poulin; Ki-Dong Lim; Juan Carlos Plana; Anna Woo; Thomas H Marwick
Journal:  J Am Coll Cardiol       Date:  2014-04-02       Impact factor: 24.094

8.  Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.

Authors:  Geeta Gulati; Siri Lagethon Heck; Anne Hansen Ree; Pavel Hoffmann; Jeanette Schulz-Menger; Morten W Fagerland; Berit Gravdehaug; Florian von Knobelsdorff-Brenkenhoff; Åse Bratland; Tryggve H Storås; Tor-Arne Hagve; Helge Røsjø; Kjetil Steine; Jürgen Geisler; Torbjørn Omland
Journal:  Eur Heart J       Date:  2016-02-21       Impact factor: 29.983

9.  Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI).

Authors:  Daniel R Messroghli; James C Moon; Vanessa M Ferreira; Lars Grosse-Wortmann; Taigang He; Peter Kellman; Julia Mascherbauer; Reza Nezafat; Michael Salerno; Erik B Schelbert; Andrew J Taylor; Richard Thompson; Martin Ugander; Ruud B van Heeswijk; Matthias G Friedrich
Journal:  J Cardiovasc Magn Reson       Date:  2017-10-09       Impact factor: 5.364

10.  Abnormal T2 mapping cardiovascular magnetic resonance correlates with adverse clinical outcome in patients with suspected acute myocarditis.

Authors:  Maximilian Spieker; Sebastian Haberkorn; Mareike Gastl; Patrick Behm; Stratis Katsianos; Patrick Horn; Christoph Jacoby; Bernhard Schnackenburg; Petra Reinecke; Malte Kelm; Ralf Westenfeld; Florian Bönner
Journal:  J Cardiovasc Magn Reson       Date:  2017-03-29       Impact factor: 5.364
View more
  7 in total

Review 1.  Heart Failure in Relation to Anthracyclines and Other Chemotherapies.

Authors:  Tolulope A Agunbiade; Raja Y Zaghlol; Ana Barac
Journal:  Methodist Debakey Cardiovasc J       Date:  2019 Oct-Dec

2.  Empagliflozin and Doxorubicin Synergistically Inhibit the Survival of Triple-Negative Breast Cancer Cells via Interfering with the mTOR Pathway and Inhibition of Calmodulin: In Vitro and Molecular Docking Studies.

Authors:  Shenouda G Eliaa; Ahmed A Al-Karmalawy; Rasha M Saleh; Mohamed F Elshal
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-11

Review 3.  Cardiotoxicity of Contemporary Breast Cancer Treatments.

Authors:  Katherine Lee Chuy; Anthony F Yu
Journal:  Curr Treat Options Oncol       Date:  2019-05-09

Review 4.  Cardiovascular Imaging in Cardio-Oncology: The Role of Echocardiography and Cardiac MRI in Modern Cardio-Oncology.

Authors:  John Alan Gambril; Aaron Chum; Akash Goyal; Patrick Ruz; Katarzyna Mikrut; Orlando Simonetti; Hardeep Dholiya; Brijesh Patel; Daniel Addison
Journal:  Heart Fail Clin       Date:  2022-07       Impact factor: 2.828

Review 5.  Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy.

Authors:  Wei Huang; Rong Xu; Bin Zhou; Chao Lin; Yingkun Guo; Huayan Xu; Xia Guo
Journal:  Front Cardiovasc Med       Date:  2022-06-10

6.  Myocardial edema during chemotherapy for gynecologic malignancies: A cardiac magnetic resonance T2 mapping study.

Authors:  Meng-Xi Yang; Qing-Li Li; Dan-Qing Wang; Lu Ye; Ke-Min Li; Xiao-Juan Lin; Xue-Sheng Li; Chuan Fu; Xin-Mao Ma; Xi Liu; Ru-Tie Yin; Zhi-Gang Yang; Ying-Kun Guo
Journal:  Front Oncol       Date:  2022-10-03       Impact factor: 5.738

Review 7.  Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer.

Authors:  Agneta Månsson Broberg; Jürgen Geisler; Suvi Tuohinen; Tanja Skytta; Þórdís Jóna Hrafnkelsdóttir; Kirsten Melgaard Nielsen; Elham Hedayati; Torbjørn Omland; Birgitte V Offersen; Alexander R Lyon; Geeta Gulati
Journal:  Curr Heart Fail Rep       Date:  2020-09-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.